Share
Ponatinib at a glance
Ponatinib, also called Iclusig, is a tyrosine kinase inhibitor, or TKI. It blocks the abnormal BCR::ABL1 protein that drives some leukaemias. It may be prescribed alone or as part of a chemotherapy plan. The choice of regimen determines the starting dose, later reductions and the other precautions you need.
Treatment is usually taken once daily, with or without food. A reduction after a good response can be an intentional part of treatment, rather than a sign that something has gone wrong. Only your specialist should change the dose.
The US prescribing information carries prominent warnings about blocked arteries, clots in veins, heart failure and liver injury. These problems can be serious or fatal. Regular assessment and early symptom reporting are essential, including for younger people without known heart disease.
What ponatinib is and how it works
BCR::ABL1 is formed when genetic material joins in an abnormal way, usually associated with the Philadelphia chromosome. The resulting protein sends growth signals that remain switched on. Ponatinib blocks its kinase activity, helping reduce the production and survival of affected cells.
Some changes in the protein can make other TKIs less effective. One important example is the T315I mutation. Ponatinib can act against this altered protein, but the mutation is not a requirement for every person prescribed the medicine. Your haematologist interprets the full diagnosis, previous responses and mutation results together.
A molecular blood test measures the amount of BCR::ABL1 material. Falling levels can show that treatment is working even when you cannot feel a difference. A very low result does not necessarily mean that treatment can be stopped. Follow-up testing remains important after any dose reduction.
How the team decides whether it is suitable
The decision balances the expected leukaemia benefit against cardiovascular and other risks. Tell the team about heart attack, stroke, procedures to reopen blood vessels, poor circulation, blood clots, high blood pressure, diabetes, high cholesterol and smoking. Ponatinib-related vessel problems can also occur without these risk factors.
Discuss liver or kidney disease, previous pancreatitis, heavy alcohol use, bleeding, eye disease and previous hepatitis B. A past heart attack or stroke requires particularly careful consideration of alternatives and benefit versus risk. Report any allergy to ponatinib or its ingredients; European guidance excludes treatment with this allergy. Mention rare inherited sugar-processing disorders because European products contain lactose.
Liver-dose instructions differ. US guidance reduces a usual 45 mg single-agent starting dose to 30 mg when pre-existing liver impairment is present. Its chemotherapy-combination guidance differs by liver severity. European information permits the recommended starting dose with caution. These are specialist decisions, not rules to apply to your own prescription. Significant kidney impairment also needs individual assessment.
Current European information includes selected children aged six years and older, with weight-based prescribing and growth monitoring. US information has not established safety and effectiveness in children. Neither an adult tablet count nor an adult response-reduction schedule should be applied to a child without the paediatric specialist's instructions.
Before treatment starts
The team reviews your cardiovascular history, examines you and checks blood pressure. Cholesterol, diabetes and other risk factors should be addressed before and during treatment. Depending on your history, an ECG, heart scan or specialist cardiac assessment may be needed. Ask whether home blood-pressure monitoring will be useful.
Baseline tests include blood counts, liver and kidney function, pancreatic enzymes such as lipase, and other blood chemistry appropriate to the regimen. Lipase helps identify inflammation of the pancreas. The team assesses tumour-lysis risk and corrects high uric acid or dehydration before starting where necessary.
European guidance recommends hepatitis B testing before treatment because a previous infection can reactivate. If results show current or past infection, liver or infection specialists can advise on prevention and monitoring. Tell the team even if hepatitis occurred years ago and you now feel well.
US guidance recommends a comprehensive eye examination before treatment and periodically afterwards. Mention pre-existing visual problems and any eye treatment. Pregnancy testing, contraception, breastfeeding and fertility plans should also be discussed before the first dose.
Bring all medicines, vitamins and herbal products to the review. Obtain written instructions for the prescribed dose, urgent contact details, temperature thresholds and what to do after a missed dose. When chemotherapy is included, you need the complete regimen's supportive-care plan as well.
How treatment is taken
A dose matched to the treatment plan
Common adult starting doses are 45 mg or 30 mg once daily, depending on the regimen. In a response-adjusted chronic-phase chronic myeloid leukaemia plan, US guidance starts at 45 mg and reduces to 15 mg after BCR::ABL1 reaches 1% or less on the International Scale. European guidance says to consider that reduction alongside cardiovascular risk, side effects and response details.
A particular Philadelphia-positive acute lymphoblastic leukaemia chemotherapy plan starts at 30 mg and reduces to 15 mg after a specified very low residual-disease result and complete remission at the end of induction, the first intensive phase. Its response threshold is 0.01%, not the 1% threshold used in the chronic-phase plan. These numbers explain why prescriptions differ; they are not instructions to change tablets after seeing a laboratory result.
Some other plans start at 45 mg and use different response or tolerability decisions. Loss of a previous response may prompt reassessment and a prescribed increase, while toxicity may require a pause, reduction or permanent stop. Do not alternate doses or restart after a pause on your own.
Tablets and the European capsule option
Take the prescribed dose at approximately the same time each day, with or without food. Swallow tablets whole with water; do not cut, crush, chew or dissolve them. Tablet strengths in the reviewed US information are 10, 15, 30 and 45 mg. Always check the strength and current tablet count when a prescription changes.
Current European information also provides a 5 mg hard capsule for paediatric dosing needs. A prescribed capsule can be swallowed whole. If the child cannot swallow it, the full contents can be sprinkled into applesauce or yogurt and taken immediately. Do not crush or dissolve the contents, save the mixture for later, or use only part of a capsule. Ask the pharmacist to demonstrate the exact preparation. These capsule instructions do not apply to tablets.
Missed doses, sickness and storage
If you miss a dose, skip it and take the next dose at the usual time the following day. Do not take two doses together. If you vomit soon after a dose, do not take a replacement; contact the team if vomiting continues or you cannot drink normally.
Keep it in its labelled packaging, away from children. US information specifies 20–25°C (68–77°F); European guidance specifies the original container to protect from moisture. Keep the moisture-absorbing canister in the bottle and never swallow it. Ask the pharmacy about safe handling and returning unused medicine. If you take too much, contact the team or hospital immediately and bring the packet. Never share the treatment.
Monitoring during treatment
Blood counts are checked every two weeks for the first three months, then monthly or as clinically needed. Chemotherapy combinations or abnormal results can require more frequent checks. Low white cells increase infection risk, low platelets increase bleeding risk, and low red cells can cause fatigue or breathlessness.
Lipase is checked every two weeks for the first two months. US guidance then recommends monthly checks or more often if needed; European information says periodically thereafter. A history of pancreatitis, heavy alcohol use or very high triglycerides may warrant additional care.
Liver tests are performed before treatment and repeatedly during it. US guidance specifies at least monthly monitoring or as clinically indicated; European guidance uses periodic assessment. Liver-affecting chemotherapy may increase the need for close follow-up.
Blood pressure, circulation, heart symptoms, fluid retention and vision are reviewed. Molecular testing measures response and informs safe dose changes. Children also need growth monitoring. Ask which results you should expect at each visit and whom to contact if a planned blood test is missed.
Common side effects and practical care
Skin, mouth and digestive symptoms
Dry skin and rash can occur. Use gentle washing products and moisturiser, and report painful or widespread changes. A rash with blisters, peeling, fever or mouth involvement needs urgent assessment rather than another cosmetic cream.
Nausea, constipation, abdominal discomfort or diarrhoea may occur. Take prescribed anti-sickness or bowel medicines as directed. Small meals may be easier when appetite is poor. Keep drinking within any fluid restriction and seek advice early if eating or drinking becomes difficult. Severe abdominal pain needs urgent assessment because it may indicate pancreatic or bowel injury.
Mouth soreness is particularly relevant in combination treatment. A soft toothbrush, gentle mouth care and prescribed rinses may help. Report ulcers, bleeding gums or pain that prevents eating; infection or a low platelet count may need treatment.
Fatigue, headache and aches
Tiredness can affect work, concentration and daily activities. Plan rest around priorities and keep gentle activity within your comfort level. Tell the team if fatigue suddenly worsens or is accompanied by breathlessness, dizziness or palpitations. Anaemia, infection or heart problems may contribute.
Headache, joint pain and muscle aches can occur. Check pain medicines with the pharmacist before using them, especially aspirin or anti-inflammatory medicines that may increase bleeding risk. A sudden severe headache, particularly with confusion or visual changes, is an emergency warning sign.
Swelling and altered sensation
Mild swelling may occur, but new or increasing ankle swelling, rapid weight gain or breathlessness should be reported promptly. Fluid can collect around the lungs or heart and may need specific treatment. Do not start water tablets yourself.
Tingling, burning, numbness or weakness may reflect nerve effects. Report these before they interfere with walking, balance, buttons or other activities. Protect numb hands and feet from burns and injury. Sudden one-sided weakness or a drooping face requires emergency stroke assessment.
Important risks to understand
Blocked vessels and heart problems
Ponatinib can cause narrowing or blockage of arteries supplying the heart, brain, limbs and other organs. Warning signs include chest pressure, sudden weakness or speech difficulty, and a painful cold or discoloured hand or foot. Clots in veins can cause one-sided leg swelling or travel to the lungs. Some vessel events occur early and others after prolonged treatment.
Heart failure can cause increasing breathlessness, difficulty lying flat, swelling or rapid weight gain. Slow, fast or irregular heart rhythms may cause palpitations, dizziness or fainting. Do not dismiss these symptoms as routine fatigue. A suspected vessel blockage needs immediate assessment and advice before the next dose. European guidance requires immediate interruption for arterial occlusion or venous thromboembolism; US stopping decisions depend on severity. Restarting requires specialist assessment.
Blood pressure can rise without symptoms. Severe hypertension with headache, confusion, chest pain or breathlessness needs urgent care. Difficult-to-control blood pressure can occasionally reflect narrowing of the kidney arteries. European information also warns about aneurysms or tears in artery walls; sudden severe chest, back or abdominal pain is an emergency.
Liver and pancreatic injury
Liver injury, including liver failure, can be fatal. Report yellow eyes or skin, dark urine, unusual itching, right-sided upper abdominal pain or marked new nausea and tiredness. Blood-test abnormalities can occur before symptoms. Treatment changes depend on severity and recovery.
Pancreatitis is inflammation of the pancreas. It often appears early but can occur later. Severe upper abdominal pain, especially spreading to the back or accompanied by vomiting, requires urgent assessment. If symptoms accompany a lipase rise, treatment is withheld while pancreatitis is investigated. An isolated enzyme rise still needs the team's interpretation.
Infection, bleeding and rapid cell breakdown
Low blood counts can be severe. Fever, shaking chills or sudden illness require urgent contact, even if you do not have a high temperature. Bleeding may occur with or without very low platelets. Vomiting blood, black stools, uncontrolled bleeding or a severe headache after a fall require immediate assessment.
Tumour lysis syndrome occurs when rapid cell breakdown releases substances that disturb blood chemistry and kidney function. Prevention may include hydration and medicines to manage uric acid, tailored to your risk. New weakness, muscle cramps, palpitations or reduced urine need urgent attention. Do not force fluids if you have been given a restriction.
Eye, brain and wound complications
Eye problems can involve the retina or its blood vessels and sometimes cause permanent visual loss. Report new blurred vision, eye pain, flashes or other visual changes promptly; sudden visual loss is an emergency. Routine eye examinations do not replace assessment of new symptoms.
A brain condition called posterior reversible encephalopathy syndrome, or PRES, can cause seizures, severe headache, confusion and vision changes. The term “reversible” does not make it safe to wait. Treatment is interrupted while the condition is assessed and managed; restarting requires specialist consideration.
Wound healing can be impaired. US instructions specify withholding ponatinib at least one week before elective surgery and for at least two weeks after major surgery, with adequate healing also required. The surgeon and haematologist must coordinate the plan, including dental surgery. A hole or abnormal connection in the gut has also been reported; severe abdominal pain with fever, vomiting or a swollen abdomen requires emergency assessment.
When to get urgent help
Seek emergency care now for chest pain, severe breathing difficulty, stroke symptoms, collapse, a seizure, sudden visual loss, a cold painful limb, major bleeding or severe persistent abdominal pain. If possible, take your medicine list and tell clinicians when the last ponatinib dose was taken, without delaying care.
Contact the hospital's urgent advice service promptly for fever at the threshold your team has given you, shaking chills, feeling suddenly unwell, jaundice, worsening swelling, new breathlessness, persistent vomiting or new numbness and weakness. If you have not been given a different threshold, call at 37.5°C (99.5°F) or higher or below 36°C (96.8°F). Follow your hospital's written rule and call if acutely unwell even with a normal temperature.
Do not wait for routine blood results to report symptoms. The assessing team should advise whether the next dose must be withheld. Following a serious event or treatment pause, do not restart without explicit instructions.
Other medicines, supplements and vaccinations
Strong CYP3A inhibitors can raise ponatinib levels, while strong inducers can lower them. Examples include certain antifungals, antibiotics, antiviral medicines, rifampicin, seizure medicines and St John's wort. US guidance advises avoiding strong inhibitors or reducing ponatinib if their use cannot be avoided; the precise adjustment depends on the current dose.
Avoid grapefruit and grapefruit juice. Ask before starting herbal or nutritional supplements. European guidance also advises caution with moderate CYP3A interactions and medicines carried by transport proteins, including some heart medicines, statins and methotrexate. The oncology pharmacist should review the whole list rather than one drug in isolation.
Do not start aspirin or a blood thinner simply because ponatinib can cause clots. It can also cause serious bleeding. If you already take an antiplatelet or anticoagulant, the team must balance the reasons for it against platelet counts and bleeding risk. Do not stop an essential medicine without advice.
Discuss vaccines with the cancer team, including travel vaccines and live vaccines. Timing and suitability depend on blood counts and other treatments. Chemotherapy partners can add infection precautions, interactions and supportive medicines beyond those described for ponatinib alone.
Everyday life during treatment
A daily reminder and a written medication list can help, particularly after a dose reduction. Check that old and new strengths are not accidentally mixed. Let the team know about missed doses honestly; this helps interpret molecular results and solve practical problems.
Do not drive or operate machinery when dizzy, drowsy or affected by visual symptoms. Gentle exercise and help with daily tasks can support energy. Smoking cessation, blood-pressure treatment and management of cholesterol or diabetes are practical parts of reducing cardiovascular risk.
Discuss alcohol because liver and pancreatic problems are important concerns. Tell your dentist about treatment before procedures, and arrange travel around tests and appointments. Emotional support, help with work and financial questions, and discussion of sexual wellbeing are also worthwhile parts of care.
Pregnancy, breastfeeding and fertility
Ponatinib can harm an unborn baby. US guidance recommends effective contraception for patients who could become pregnant during treatment and for three weeks after the final dose. European guidance advises avoiding pregnancy or fathering a child during treatment, and using an alternative or additional method because effects on hormonal contraception are uncertain. Ask for a written plan covering both partners and any chemotherapy.
Tell the team immediately if pregnancy occurs or is suspected. Current European information includes reports of Hirschsprung's disease, a birth defect affecting nerves in the baby's large bowel, after exposure in early pregnancy. The available human data are limited and do not give a reliable individual risk estimate. Specialist advice is needed.
Do not breastfeed during treatment. US information specifies avoiding breastfeeding for one week afterwards; European information gives no fixed post-treatment interval. Agree a safe restart date with your team. Animal studies suggest possible effects on female fertility, with uncertain relevance and reversibility in people. Discuss fertility preservation before treatment where feasible.
After treatment stops
Follow-up depends on why ponatinib stopped and the next treatment plan. Molecular tests, blood counts and monitoring of any liver, heart or pancreatic problem may continue. If you carry hepatitis B, monitoring may be needed for several months after treatment ends.
Continue the agreed pregnancy and breastfeeding precautions. Do not independently stop blood-pressure medicines or restart ponatinib left in the bottle. Retain details of serious reactions so future teams can make informed decisions, and return unwanted medicine to the pharmacy.
Frequently asked questions
1. Is Iclusig the same as ponatinib?
Yes. Iclusig is a verified brand of ponatinib. Check both the generic name and strength on your packet because different tablet strengths can change the number you need to take.
2. Must I have the T315I mutation?
Not always. Ponatinib can act against T315I, but other clinical circumstances can support its use. The specialist considers the full diagnosis, earlier treatments and test results rather than one mutation in isolation.
3. Why did my dose fall after a good response?
A planned reduction can maintain disease control while reducing exposure and some risks. The required response differs between regimens. Continue molecular monitoring and take only the dose your team has prescribed.
4. Are the 1% and 0.01% response targets interchangeable?
No. They belong to different treatment contexts and response definitions. A laboratory number alone does not tell you to change dose. Your haematologist combines it with remission status and the treatment phase.
5. Must I avoid food around the dose?
No. Ponatinib can be taken with or without food. Taking it at a consistent time may help you remember it. Food instructions for other leukaemia medicines must not be copied onto ponatinib.
6. Can I crush a tablet if swallowing is difficult?
No. Tablets must remain whole. Ask the pharmacist for help. The European capsule-opening option has specific instructions and does not mean tablets can be crushed or dissolved.
7. How are the new European capsules given?
The prescribed 5 mg capsules can be swallowed whole. For a child unable to swallow them, sprinkle the full contents into applesauce or yogurt and give immediately. Do not crush, dissolve or save the contents.
8. What if I forget a dose or vomit?
Do not double a missed dose or replace a vomited dose. Take the next scheduled dose normally. Report repeated sickness, especially with abdominal pain or difficulty drinking.
9. Can vessel problems happen without previous heart disease?
Yes. Serious blockages have occurred in younger people and in people without known risk factors. Risk-factor management is important, but everyone needs to recognise urgent symptoms.
10. Should I start aspirin to prevent clots?
Not unless your treating clinician recommends it. Ponatinib can also cause bleeding and low platelets. The decision must consider your individual reasons for aspirin and your current blood results.
11. Why do I need lipase tests?
Lipase can rise when the pancreas is affected. Regular early testing helps identify a problem, but severe abdominal pain still needs urgent assessment even if the last result was normal.
12. Is breathlessness always due to anaemia?
No. Infection, a lung clot, heart failure or fluid around the lungs are also possible. New breathlessness needs prompt assessment; sudden or severe breathing difficulty is an emergency.
13. What vision changes should I report?
Report new blurring, eye pain, flashes or other changes promptly. Sudden visual loss needs emergency care because a blocked retinal vessel or another serious problem may be responsible.
14. Why am I being tested for hepatitis B?
A previous infection can reactivate during BCR::ABL1-targeted treatment. Testing helps identify people who need specialist prevention or monitoring, including after treatment stops. Feeling well does not exclude a past infection.
15. Can I have an operation while taking ponatinib?
It requires a coordinated plan. US guidance includes at least a week off before elective surgery and at least two weeks after major surgery, plus adequate healing. Do not choose restart dates yourself.
16. Are tingling fingers important?
Yes. Tingling, burning or numbness can signal nerve toxicity. Reporting early may help prevent worsening. Sudden weakness on one side, especially with speech or facial changes, needs emergency stroke assessment.
17. Are children's doses the same as adults'?
Not automatically. Current European paediatric prescribing uses body weight and response, with growth monitoring. US information has not established paediatric use. A specialist must specify the product and dose for each child.
18. Can I take an antibiotic or antifungal prescribed elsewhere?
Have it checked promptly against ponatinib. Some strongly change its blood level and may require an alternative or a prescribed dose adjustment. Tell the new prescriber about all your cancer medicines.
19. How long are pregnancy precautions needed?
US guidance gives three weeks after the last dose for patients who could become pregnant. European guidance and partner medicines require an individual contraception plan. Do not assume the same interval covers both partners or every chemotherapy drug.
20. Can I stop after an excellent molecular result?
Not on your own. A very low result may support a planned dose reduction, but it does not automatically mean treatment can end. Ask what follow-up and response milestones apply to your particular regimen.
Sources and review information
Sources checked: 1 October 2026. Read with the leaflet for your prescribed formulation and your hospital’s treatment plan.
